Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Low-Dose IL-2 Effective in Treatment of SLE

Key clinical point: Low-dose recombinant interleukin-2 proved safe and effective for treatment of SLE in a randomized trial.

Major finding: The median SLEDAI score improved from 12 at baseline to 4 at week 24.

Study details: This randomized, double-blind, placebo-controlled clinical trial comprised 60 patients with SLE.

Disclosures: The presenter reported having no financial conflicts regarding her study.


Reporting from LUPUS 2019